The Efficacy And Safety Of Erenumab In Preventive Treatment Of Migraine: A Meta-analysis

Objective:To evaluate the efficacy and safety of erenumab in the preventive treatment of migraine by meta-analysis.Methods:Searching for related articles about erenumab preventive treatment of migraine from CNKI,Wanfang Database,CBM,VIP,PubMed,Embase,Cochrane Library and other databases published from January 2010 to October 2020 by computer.The language is limited to Chinese and English.According to the inclusion and exclusion criteria,the literatures that meet the criteria are screened out,then the full text is read in detail and the effective data are extracted,and the meta analysis is carried out by using Revman5.3 and Stata15 software.Results:Finally,a total of 6 articles were included,there were 3403 patients,including 2086 in the experimental group and 1317 in the control group.The results of meta-analysis showed that in terms of efficacy,migraine days per month Change from baseline decreased significantly after the application of 70 and 140mgerenumab(MD=-1.76,95%confidence interval was-2.09～1.43,P<0.00001),≥50%Reduction from baseline in migraine days per month were significantly increased(RR=1.71,95%confidence interval was 1.55～1.89,P<0.00001).Days of use of acute migraine-specific medication per month Change from baseline were significantly reduced(MD=-1.62,95%confidence interval was-2.01～1.24,P<0.00001).After the application of 140mg erenumab,the score of Migraine Physical Function Impact Diary everyday-activities domain(MPFID-EA)decreased significantly(MD=-3.30,95%confidence interval was-4.67～-1.92,P<0.00001),and the score of Migraine Physical Function Impact Diary physical-impairment domain(MPFID-PI)decreased significantly(MD=-2.95,95%confidence interval-4.02～1.87,P<0.00001).In terms of safety:after the application of 70 and 140mgerenumab,there was no significant difference in adverse events and no increase in the incidence of adverse events compared with the control group(RR=1.00,95%confidence interval was 0.94～1.06,P=0,95>0.05),and there was no significant difference in serious adverse events between the experimental group and the control group.(RR=0.82,95%confidence interval was 0.52～0.30,P=0.40>0.05).There was no significant difference in Adverse events leading to treatment discontinuation between the experimental group and the control group,and the use of this drug did not increase the incidence of adverse events leading to treatment discontinuation(RR=1.10,95%confidence interval was 0.65～1.85,P=0.73>0.05).Among the adverse reactions caused by 70mg and 140mg erenumab,only constipation and injection site pain in the erenumab group were higher than those in the placebo group,and there was no significant difference in the other adverse reactions between the two groups.Conclusion:Erenumab is effective and safe in the preventive treatment of migraine.